<--- Back to Details
First PageDocument Content
Glycogen storage disease type II / Lysosomal storage disease / Acid alpha-glucosidase / Newborn screening / Screening / Medical genetics / Medicine / Health / Rare diseases
Date: 2012-01-07 00:54:21
Glycogen storage disease type II
Lysosomal storage disease
Acid alpha-glucosidase
Newborn screening
Screening
Medical genetics
Medicine
Health
Rare diseases

EVIDENCE REVIEW: POMPE DISEASE

Add to Reading List

Source URL: www.hrsa.gov

Download Document from Source Website

File Size: 158,49 KB

Share Document on Facebook

Similar Documents

Medicine / Health / Clinical medicine / Rare diseases / Porphyrias / Lysosomal storage diseases / RTT / Erythropoietic protoporphyria / Glycogen storage disease type II / Disease

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

Biology / Cell biology / Anatomy / Cellular processes / Vesicles / NPC1 / Cardiology / Lipoproteins / Cholesterol / Lysosomal storage disease / LAMP1 / Low-density lipoprotein

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

Mucopolysaccharidosis / Hunter syndrome / Hurler syndrome / Morquio syndrome / Sanfilippo syndrome / Maroteaux–Lamy syndrome / Genetic disorder / Lysosomal storage disease / Sly syndrome / Health / Syndromes / Rare diseases

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

Genetic genealogy / BioMarin Pharmaceutical / Glycogen storage disease type II / Acid alpha-glucosidase / Lysosomal storage disease / Mucopolysaccharidosis / Alglucosidase alfa / Neuronal ceroid lipofuscinosis / Tetrahydrobiopterin / Health / Rare diseases / Medicine

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document